Posted by Michael Wonder on 02 May 2022
Sage Therapeutics and Biogen initiate rolling submission of new drug application to US FDA for zuranolone for the potential treatment of major depressive disorder
2 May 2022 - The companies expect to complete submission of the new drug application for treatment of major depressive disorder in the second half of 2022; associated filing for post-partum depression anticipated in the first half of 2023
Sage Therapeutics and Biogen initiated a rolling submission of a new drug application to the U.S. FDA for zuranolone in the treatment of major depressive disorder.
